Skip to main content
OpenTrials
Completed

NCT Number: NCT06036758

VIDAS® NEPHROCLEAR Diagnostic Accuracy Study

This is a multi-center sample analysis study in which urine samples previously collected from persons with Stage 2 or Stage 3 Acute Kidney Injury (AKI), will be tested in order to validate the VIDAS® NEPHROCLEAR™ CCL14 Test

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

George Washington University, Washington D.C., District of Columbia, United States

Loading trial locations.

About this study

The VIDAS® NEPHROCLEAR™ CCL14 Test is intended to be used in conjunction with clinical evaluation, in ICU patients with moderate to severe (stage 2 or 3) acute kidney injury (AKI), as an aid in the risk assessment for developing persistent severe AKI (stage 3 AKI lasting ≥ 72 hours) within 48 hours of patient assessment.

The VIDAS® NEPHROCLEAR™ CCL14 Test is intended to be used in patients 21 years of age or older.

The objective of this study is to evaluate the diagnostic accuracy of the VIDAS® NEPHROCLEAR™ CCL14 test when used on the VIDAS® 3 instrument. Sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), likelihood ratios (LR), and relative risk (RR), will be evaluated at the pre-determined cut-off values.

Previously collected urine samples from persons with Stage 2 to Stage 3 AKI will be tested in this study. The VIDAS® test results will be compared to the clinical AKI status established by independent adjudication by medical professionals, that are blinded to the VIDAS® test results.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females 21 years of age or older;
  • Receiving care in an intensive care unit;
  • Expected to remain in the ICU for at least 48 hours after enrollment;
  • Use of indwelling urinary catheter as standard care at the time of enrollment;
  • Subject must have acute kidney injury (KDIGO Stage 2 or Stage 3) at the time of sample collection;
  • Urine sample must be collected within 36 hours of meeting KDIGO Stage 2 criteria;
  • Documented informed consent provided by patient or legally authorized representative (LAR).

Exclusion criteria

  • Prior kidney transplantation;
  • Comfort-measures-only status;
  • Already receiving dialysis (either acute or chronic) or in imminent need of dialysis at the time of enrollment;
  • Known infection with human immunodeficiency virus (HIV) or active hepatitis (acute or chronic); (NOTE: HIV or hepatitis testing need not be performed for enrollment in this study.)
  • Special populations, pregnant women, prisoners or institutionalized individuals;

Treatment and study plan

VIDAS® NEPHROCLEAR™ CCL14 Test

Diagnostic Test

Urine samples previously collected from persons with stage 2/stage 3 AKI will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test

Primary outcomes

  1. Risk of developing persistent severe AKI

    Time frame: Within 48 hours of ICU admittance

    The urine sample collected from ICU patients will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test, which is intended to be used in conjunction with clinical evaluation, in ICU patients with moderate to severe (stage 2 or 3) acute kidney injury (AKI), as an aid in the risk assessment for developing persistent severe AKI (stage 3 AKI lasting ≥ 72 hours) within 48 hours of patient assessment

Sponsors and collaborators

Lead sponsor

BioMérieux

Industry

Registry information

Official study title

VIDAS® NEPHROCLEAR CCL14 Diagnostic Accuracy Study

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Sep 14, 2023
Registry last updated
Feb 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.